Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
22. November 2022 12:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
18. November 2022 13:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
07. November 2022 09:00 ET
|
Cassava Sciences, Inc.
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN,...
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
03. November 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against...
Cassava Sciences Announces Expansion of Leadership Team
27. Oktober 2022 09:15 ET
|
Cassava Sciences, Inc.
Chris Cook, A Skilled Litigator, To Join Management Team as General CounselNew Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas, Oct. 27, 2022 (GLOBE...
Cassava Sciences Announces Initiation of an Open-label Extension Study
13. Oktober 2022 09:15 ET
|
Cassava Sciences, Inc.
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100 mgUp to 1,600 Patients Are Expected to Enroll AUSTIN, Texas,...
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
08. September 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
No Evidence of Data Manipulation in Science Publication on Simufilam
18. August 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of...
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
03. August 2022 09:15 ET
|
Cassava Sciences, Inc.
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months...
Cassava Sciences Responds to Media Reports
27. Juli 2022 13:36 ET
|
Cassava Sciences, Inc.
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. ...